Study
| Multicenter, open-label, single-arm trial |
| Adults with relapsed or refractory multiple myeloma who have received at least four prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody. |
| Talquetamab-tgvs(n=187); Cohort 1: talquetamab 0.4 mg/kg/weekly (n=100); Cohort 2: talquetamab 0.8 mg/kg/weekly (n=87) |
Efficacy
| Cohort 1 |
| ORR:73% [63.2-81.4] |
| mDoR: 9.5 mos [6.5-NR] |
| Cohort 2 |
| ORR:73.6% [63-82.4] |
| mDoR: NR |
Safety
| Any grade: CRS (>20%), dysgeusia (>20%), nail disorder (>20%),musculoskeletal pain (>20%), upper respiratory infection (>20%) |
Article has not yet been published
Article has not yet been published
http://www.ncbi.nlm.nih.gov/pubmed/0
Reviewed by Elvin Chalabiyev, MD on Sep 23, 2023
